DAIICHI SANKYO EUROPE GmbH
STOCKHOLM, September 1, 2010 - DAIICHI SANKYO announced today that the ongoing trials ENGAGE AF-TIMI 48
(The Effective Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation) and HOKUSAI VTE with their investigational factor Xa inhibitor
edoxaban are enrolling in accordance to plan.
TOKYO, Japan and EDISON, New Jersey, February 3 - Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has
initiated a new large-scale pivotal Phase III trial for edoxaban, its
investigational oral Factor Xa inhibitor.
MUNICH, Germany -
- Pan-European Osteoporosis Patients Encouraged to Dance Their Way to Stronger Bones
An educational programme available on DVD is launched today, on World Osteoporosis Day, bringing together the glamorous world of ballroom dance with the serious nature of disease management.
BARCELONA, Spain -
- New Treatment Could Offer Further Option in Addition to Current Standard of Care in Thromboembolic Disease
Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor Xa next GEneration in Atrial Fibrillation) as a potential new treatment for stroke prevention in patients with atrial fibrillation (AF).
